Overview

Dena Sharp is a problem solver who simplifies even the most complicated issues in class action litigation.

Dena currently represents prescription drug purchasers as co-lead counsel in In re Restasis Antitrust Litigation and as a member of the End-Payer Steering Committee in In re Generic Pharmaceuticals Pricing Antitrust Litigation, a massive price-fixing case against dozens of drug companies. She also represents clients of a fertility center whose eggs and embryos were affected by a freezer tank malfunction.

As co-lead counsel in In re Lidoderm Antitrust Litigation, a “pay-for-delay” antitrust case that settled for $104.75 million on the eve of trial, Dena worked with her team to win class certification, defeat summary judgment, and obtain the largest recovery for a class of end-payers in similar federal litigation in more than a decade. She has also played a key role in a variety of other high-profile cases, including representing investors in litigation arising from Lehman Brothers’ bankruptcy and in matters involving Ponzi schemes and accounting fraud.

Outside the courtroom, Dena is co-author of the widely-cited Sedona Principles: Best Practices and Principles for Electronic Document Production (Third Edition). She serves on the board of directors of the Impact Fund, a public interest nonprofit, and as vice chair of the Advisory Council for the Duke Law School Center for Judicial Studies. An editor of the Duke Law Proportionality Guidelines and Best Practices, Dena is also co-author of a chapter in a forthcoming ABA book on class action practice and strategy.

A first-generation American, Dena is fluent in Spanish and German.

Clerkships

  • Externed for the Honorable Phyllis J. Hamilton of the Northern District of California
  • Externed for the Honorable John E. Munter of the San Francisco Superior Court

Education

J.D., cum laude, University of California, Hastings College of Law

  • Thurston Honors Society
  • Best Oral Advocate Award
  • Witkin Award in Legal Writing and Criminal Law courses

B.A., magna cum laude, Brown University

Admissions

  • California
  • Northern District of California
  • Central District of California
  • Southern District of California
  • Eastern District of California
  • District of Colorado
  • Northern District of Illinois
  • Courts of Appeals for the Ninth and Tenth Circuits

Languages

  • Spanish
  • German

Experience

In re Restasis Antitrust Litigation
Co-lead counsel in this monopolization case against pharmaceutical giant Allergan for its multifaceted strategy to delay generic competition in the market for the blockbuster drug Restasis.

In re Lidoderm Antitrust Litigation
Co-lead counsel in this “pay-for-delay” litigation against three drug companies. Settled a week before jury selection only after the class was certified and summary judgment had been denied. The $104.75 million settlement represents the largest end-payer recovery in absolute and percentage terms in any federal pay-for-delay case in at least the past decade.

In re Generic Pharmaceuticals Pricing Antitrust Litigation
Member of the End-Payer Plaintiffs’ Steering Committee in this massive price-fixing case against dozens of drug companies, where executives have pleaded guilty to collusion and 48 state attorneys general have alleged a sprawling conspiracy on the part of the drug makers.

In re Pacific Fertility Litigation
Representing plaintiffs who allege their frozen eggs and embryos were affected by the failure of a cryopreservation tank at Pacific Fertility Center’s San Francisco clinic in early March 2018. 

In re Capacitors Antitrust Litigation
Representing direct purchasers in a multidistrict proceeding that follows several executives pleading guilty to fixing the prices of capacitors, tiny electronic components found in devices from toasters to cell phones. Nearly $100 million in settlements to date and the case is proceeding to trial.

In re Lehman Brothers Holdings Securities and ERISA Litigation
Lead counsel for investors in the securities litigation arising from the largest bankruptcy in United States history. Recovered $120 million on behalf of structured note investors and helped secure total recoveries of over $700 million

In re Oppenheimer California Fund Securities Litigation
Co-lead counsel for investors in Oppenheimer’s California Municipal Bond Fund, which misled investors about its investment risk and then lost nearly half its value. Recovered $50.75 million for the certified class of investors.

In re Provident Royalties, LLC / Medical Capital
Lead counsel team for the plaintiffs in this Ponzi scheme litigation, ultimately recovering $150 million for investors.

In re SLM Corporation Securities Litigation
Lead counsel team in accounting fraud litigation brought under Rule 10b-5 that resulted in a $35 million recovery.

Honors and Awards

Honors and Awards

  • Named to the Northern California Super Lawyers list (2017-2018)
  • Named to the Northern California Rising Stars list (2009-2016)

Affiliations

Community & Professional

  • Impact Fund 
    • Member, Board of Directors
    • Member, Grant Advisory Committee
    • Chair, Development Committee
  • Vice chair, Duke Law Bolch Judicial Institute, Advisory Council for the Duke Conferences
  • Member, The Sedona Conference, Working Group 1 on Electronic Document Retention and Production
  • American Bar Association
    • Member, Sections on Antitrust, Securities Litigation, and Pretrial Practice and Discovery
    • Former vice chair, Young Lawyer’s Division Litigation Committee 
  • Member, Federal Bar Association, Northern District of California Chapter
  • Member, State Bar of California, Litigation Section

Insights

Speaking Engagements

  • 11.2018
  • “Upon a Showing of Deficiency: Discovery on Discovery and Responses,” course instructor
    2018
  • “How Far Can Self-Reliance Get You?” Panelist
    06.2018
  • “Managing the Haystack: How to Get the Most out of Electronic Discovery,” moderator
    02.2018
  • “Bench-Bar Experiences with the 2015 Discovery Proportionality Amendments,” participant
    12.2017
  • “Class Action Settlement Notice and the Extinction of ‘preliminary Approval,’” panelist
    08.2017
  • 02.2017
  • “Class Actions Gone Wrong,” panelist
    02.2017
  • “Interpreting Rule 37(e): What Have We Learned from Six Months of Decisions?” panelist
    06.2016
  • 04.2016
  • “The Sedona Principles, Third Edition,” panelist
    04.2016
  • 12.2015
  • “Amending the Federal Rules: Intended and Unintended Consequences,” panelist
    12.2015
  • 10.2015
  • “Update on the Sedona Principles, Third Edition,” panelist
    04.2015
  • 03.2015
  • “Applying the Proportionality Factors,” panelist
    11.2014
  • Civil litigation seminar, guest lecturer
    University of California Berkeley School of Law and University of California Hastings School of Law
    09.2014
  • “Lawyering on the Plaintiffs’ Side,” panelist
    10.2013
  • “6th Annual Staying Ahead of the eDiscovery Curve Program,” faculty
    03.2012

Publications

Main Menu